{
  "Country": "EN",
  "PICOs": [
    {
      "Population": "Adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation who have progressed after at least one prior systemic therapy, including platinum-based chemotherapy or anti-PD-1/PD-L1 immunotherapy.",
      "Intervention": "Sotorasib",
      "Comparator": "Docetaxel or docetaxel plus nintedanib",
      "Outcomes": "Increased time before cancer progression and improved overall survival; potential for cost-effectiveness and life extension at the end of life."
    }
  ],
  "SourceType": "clinical_guideline"
}